What is ENSC's market cap?

$7.19M, based on the Nov 4 close of $0.37.

Does Ensysce Biosciences pay a dividend?

No regular cash dividend has been paid in the last year.

How much of ENSC is sold short?

304.0K shares, 2.1% of float, as of Oct 15, 2026.

What sector is ENSC in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · ENSCHealthcarePharmaceuticals

Ensysce Biosciences, Inc. Common Stock (ENSC)

$0.3697−2.12%

Close Nov 4, 2026 · split-adjusted

Oct 30, 2026$0.42▼ 80.42% in range

Nov 3, 2025Low $0.25 · High $2.15Oct 30, 2026

What changed · written from our data

As of Nov 4, 2026

Ensysce Biosciences closed at $0.37 on Nov 4, down 2.12%, 82.8% below its 52-week closing high. Volume of 147.6K shares was 0.26× its 20-day average (below normal).

Split-adjusted performance: -14.0% over one month, -5.2% over six months, -82.8% over one year.

In the quarter ended Jun 30, 2026, revenue was $1.16M, down 15.1% from a year earlier, with a net margin of -220.8%.

Short interest was 304.0K shares at the Oct 15 settlement, down 71.9% from the prior report (2.1% of float, 1.0 days to cover).

Market cap$7.2M19.5M shares

Revenue · quarter$1.2M−15.1% YoY

Diluted EPS$-0.20—

P/E · TTM—P/S 1.6×

Net margin-220.8%Gross 100.0%

Dividend yieldNone

52-week range0.25 – 2.15−82.8% from high

Volume147.6K0.26× 20-day avg

Volatility · 60d89.5%Annualised

Short % of float2.1%1.0 days to cover

Net cash$479.9KCash $676.7K

Next earnings—Not scheduled

Split-adjusted performance

1W −18.3%1M −14.0%3M −29.5%6M −5.2%YTD −59.8%1Y −82.8%3Y −97.3%5Y −100.0%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum68

Revenue growth31

Net margin37

Value (low P/E)—

Size12

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short304.0K−71.9% vs prior

Days to cover1.0Settled Oct 15

% of float2.1%

Short vol. 10d24.8%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
ENSCEnsysce Biosciences	$0.3697	−2.12%	−5.2%	−15.1%	−220.8%	—	$7.2M
KPRXKiora Pharmaceuticals	$1.66	−4.05%	−33.9%	—	—	—	$7.3M	Compare
ALZNAlzamend Neuro	$1.53	+4.79%	+39.1%	—	—	—	$7.4M	Compare
NAIINatural Alternatives International	$1.10	+3.77%	−59.6%	+1.9%	−39.2%	—	$6.9M	Compare
FBLGFibroBiologics	$0.9685	−2.17%	−24.9%	—	—	—	$6.9M	Compare
SNGXSoligenix	$0.3508	−1.49%	+6.0%	—	—	—	$7.6M	Compare
ENVBEnveric Biosciences	$1.46	−2.67%	−54.1%	—	—	—	$6.5M	Compare
XCURExicure	$0.9928	−1.70%	−70.7%	—	—	—	$6.5M	Compare
APREAprea Therapeutics	$0.5052	−1.90%	−39.4%	−100.0%	—	—	$6.4M	Compare

News about Ensysce Biosciences

All news →

Tiny Pain-Focused Biotech Ensysce Biosciences Surges Amid Strategic ReviewBenzinga · Feb 27, 2026▲ Positive

Quick answers

What does Ensysce Biosciences do?: Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, opioids that prevent both drug abuse and overdoses.
What is ENSC's market cap?: $7.19M, based on the Nov 4 close of $0.37.
Does Ensysce Biosciences pay a dividend?: No regular cash dividend has been paid in the last year.
How much of ENSC is sold short?: 304.0K shares, 2.1% of float, as of Oct 15, 2026.
What sector is ENSC in?: Healthcare, in the Pharmaceuticals industry.

About Ensysce Biosciences

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

HQ: La Jolla, CA10 employeesListed Jul 1, 2021ensysce.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology